• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Rapport Therapeutics, Inc. - Common Stock (NQ:RAPP)

    30.20 +1.21 (+4.17%)
    Streaming Delayed Price Updated: 4:00 PM EST, Feb 25, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 201,359
    Open 29.31
    Bid (Size) 25.90 (100)
    Ask (Size) 31.90 (100)
    Prev. Close 28.99
    Today's Range 29.03 - 30.55
    52wk Range 6.430 - 42.27
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Rapport Therapeutics to Participate in Upcoming Investor Conferences
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +7.4%
    +7.4%
    1 Month
    +14.2%
    +14.2%
    3 Month
    +5.7%
    +5.7%
    6 Month
    +88.6%
    +88.6%
    1 Year
    +128.1%
    +128.1%

    More News

    Read More
    News headline image
    Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally
    Via MarketMinute
    Topics ETFs Economy Intellectual Property
    News headline image
    Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    This Extreme Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
    Via Benzinga
    News headline image
    Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally
    Via MarketMinute
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Rapport Therapeutics Inc (NASDAQ:RAPP) Reports Q3 2025 Earnings Beat and Positive Phase 2a Seizure Data ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics to Participate in Upcoming Investor Conferences
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
    Via Benzinga
    News headline image
    Rapport Announces Pricing of Public Offering of Common Stock
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Let's take a look at the stocks that are in motion in today's session. ↗
    Via Chartmill
    News headline image
    Rapport Announces Proposed Public Offering of Common Stock
    From Rapport Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Top movers analysis one hour before the close of the markets on 2025-09-08: top gainers and losers in today's session. ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Monday's Intraday Session ↗
    Via Benzinga
    News headline image
    Top stock movements in today's session. ↗
    Via Chartmill
    News headline image
    Gold Moves Higher; Robinhood Shares Jump ↗
    Via Benzinga
    News headline image
    Rapport Therapeutics, Planet Labs, QuantumScape, EchoStar And Other Big Stocks Moving Higher On Monday ↗
    Via Benzinga
    News headline image
    Nasdaq Surges 150 Points; Planet Labs Shares Jump After Q2 Results ↗
    Via Benzinga
    News headline image
    Rapport Catapults Almost 200% After Succeeding In Hard-To-Treat Seizures ↗
    Via Investor's Business Daily
    News headline image
    Rapport Reports Promising Epilepsy Study Outcomes, Plans Phase 3 Trials Next Year ↗
    Via Benzinga

    Frequently Asked Questions

    Is Rapport Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Rapport Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Rapport Therapeutics, Inc. - Common Stock trade on?
    Rapport Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Rapport Therapeutics, Inc. - Common Stock?
    The ticker symbol for Rapport Therapeutics, Inc. - Common Stock is RAPP on the Nasdaq Stock Market
    What is the current price of Rapport Therapeutics, Inc. - Common Stock?
    The current price of Rapport Therapeutics, Inc. - Common Stock is 30.20
    When was Rapport Therapeutics, Inc. - Common Stock last traded?
    The last trade of Rapport Therapeutics, Inc. - Common Stock was at 02/25/26 04:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.